Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)

Amandeep Salhotra; Ahmed Aribi; Dat Ngo; Jianying Zhang; Karamjeet Sandhu; Monzr Al-Malki; Haris Ali; Paul Koller; Shukaib Arslan; Elizabeth Budde; Samer Khaled; Sanjeet Dadwal; David S. Snyder; Andrew Artz; Stephen Forman; Ryotaro Nakamura; Anthony Stein; Guido Marcucci; Ibrahim Aldoss; Vinod Pullarkat

doi:10.1002/ajh.26157

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)

Amandeep Salhotra
, Ahmed Aribi
, Dat Ngo
, Jianying Zhang
, Karamjeet Sandhu
, Monzr Al-Malki
, Haris Ali
, Paul Koller
, Shukaib Arslan
, Elizabeth Budde
, Samer Khaled
, Sanjeet Dadwal
, David S. Snyder
, Andrew Artz
, Stephen Forman
, Ryotaro Nakamura
, Anthony Stein
, Guido Marcucci
, Ibrahim Aldoss
, Vinod Pullarkat

Center for Clinical and Translational Science

Research output: Contribution to journal › Letter › peer-review

18 Scopus citations

Original language	English
Pages (from-to)	E196-E200
Journal	American Journal of Hematology
Volume	96
Issue number	6
DOIs	https://doi.org/10.1002/ajh.26157
State	Published - Jun 1 2021

Access to Document

10.1002/ajh.26157

Cite this

Salhotra, A., Aribi, A., Ngo, D., Zhang, J., Sandhu, K., Al-Malki, M., Ali, H., Koller, P., Arslan, S., Budde, E., Khaled, S., Dadwal, S., Snyder, D. S., Artz, A., Forman, S., Nakamura, R., Stein, A., Marcucci, G., Aldoss, I., & Pullarkat, V. (2021). Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351). American Journal of Hematology, 96(6), E196-E200. https://doi.org/10.1002/ajh.26157

@article{53dddd56b3804ffc869c59ea31c39f6f,

title = "Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)",

author = "Amandeep Salhotra and Ahmed Aribi and Dat Ngo and Jianying Zhang and Karamjeet Sandhu and Monzr Al-Malki and Haris Ali and Paul Koller and Shukaib Arslan and Elizabeth Budde and Samer Khaled and Sanjeet Dadwal and Snyder, \{David S.\} and Andrew Artz and Stephen Forman and Ryotaro Nakamura and Anthony Stein and Guido Marcucci and Ibrahim Aldoss and Vinod Pullarkat",

note = "Funding Information: A.S.: has research funding from Bristol Myers Sqibb, serves on advisory board of Syros and advisor for Kadmon, A.A.: consultancy for Seattle Genetics, M.A.L.: consultancy for Neximmune, Riegel pharma and Jazz pharmaceuticals, H.A. consultancy for Incyte corporation, E.B.: Consultancy for Gilead, Mustang and Roche, Research funding Merck, Amgen and Kite. S.S.D.: Research funding Ansun Biopharma, Karius, Shire/Takeda, Gilead, Chimrex, R.N.: Advisory board, Merck, Magenta therapeutics, Kadmon Napajen pharma: consultancy Viracor, ASS serves on the speaker bureau for Stemline, Amgen and Celgene, and on advisory boards for Stemline and Amgen. G.M. is a member of the speakers' bureau for AbbVie and Novartis and serves on advisory board with Janssen Pharm. I.A. advisory boards AbbVie, Amgen, KiTE pharmaceuticals, Agios, consultant for Autolus and Amgen, speaker for Jazz Pharmaceuticals. V.P. advisory boards for AbbVie, Jazz Pharmaceuticals, Pfizer, Genentech; member of speakers' bureau for Jazz, Amgen, Novartis and AbbVie. Consultant for Dova, Amgen. The remaining authors declare no conflict of interest. ",

year = "2021",

month = jun,

day = "1",

doi = "10.1002/ajh.26157",

language = "English",

volume = "96",

pages = "E196--E200",

journal = "American Journal of Hematology",

issn = "0361-8609",

number = "6",

}

Salhotra, A, Aribi, A, Ngo, D, Zhang, J, Sandhu, K, Al-Malki, M, Ali, H, Koller, P, Arslan, S, Budde, E, Khaled, S, Dadwal, S, Snyder, DS, Artz, A, Forman, S, Nakamura, R, Stein, A, Marcucci, G, Aldoss, I & Pullarkat, V 2021, 'Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)', American Journal of Hematology, vol. 96, no. 6, pp. E196-E200. https://doi.org/10.1002/ajh.26157

TY - JOUR

T1 - Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)

AU - Salhotra, Amandeep

AU - Aribi, Ahmed

AU - Ngo, Dat

AU - Zhang, Jianying

AU - Sandhu, Karamjeet

AU - Al-Malki, Monzr

AU - Ali, Haris

AU - Koller, Paul

AU - Arslan, Shukaib

AU - Budde, Elizabeth

AU - Khaled, Samer

AU - Dadwal, Sanjeet

AU - Snyder, David S.

AU - Artz, Andrew

AU - Forman, Stephen

AU - Nakamura, Ryotaro

AU - Stein, Anthony

AU - Marcucci, Guido

AU - Aldoss, Ibrahim

AU - Pullarkat, Vinod

N1 - Funding Information: A.S.: has research funding from Bristol Myers Sqibb, serves on advisory board of Syros and advisor for Kadmon, A.A.: consultancy for Seattle Genetics, M.A.L.: consultancy for Neximmune, Riegel pharma and Jazz pharmaceuticals, H.A. consultancy for Incyte corporation, E.B.: Consultancy for Gilead, Mustang and Roche, Research funding Merck, Amgen and Kite. S.S.D.: Research funding Ansun Biopharma, Karius, Shire/Takeda, Gilead, Chimrex, R.N.: Advisory board, Merck, Magenta therapeutics, Kadmon Napajen pharma: consultancy Viracor, ASS serves on the speaker bureau for Stemline, Amgen and Celgene, and on advisory boards for Stemline and Amgen. G.M. is a member of the speakers' bureau for AbbVie and Novartis and serves on advisory board with Janssen Pharm. I.A. advisory boards AbbVie, Amgen, KiTE pharmaceuticals, Agios, consultant for Autolus and Amgen, speaker for Jazz Pharmaceuticals. V.P. advisory boards for AbbVie, Jazz Pharmaceuticals, Pfizer, Genentech; member of speakers' bureau for Jazz, Amgen, Novartis and AbbVie. Consultant for Dova, Amgen. The remaining authors declare no conflict of interest.

PY - 2021/6/1

Y1 - 2021/6/1

UR - https://www.scopus.com/pages/publications/85104033573

U2 - 10.1002/ajh.26157

DO - 10.1002/ajh.26157

M3 - Letter

C2 - 33719090

AN - SCOPUS:85104033573

SN - 0361-8609

VL - 96

SP - E196-E200

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 6

ER -

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)

Access to Document

Other files and links

Cite this